Where can I listen to this podcast?

This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

No, this podcast does not typically feature guests.

EP Edge™ The Signal

Claim This Podcast

by Niraj Sharma MD FACC FHRS: Cardiac Electrophysiologist

11 episodes

Updated Daily

Accepts GuestsHas Sponsors

Podcast Overview

Monthly clinical deep analysis in cardiac electrophysiology: AF, VT, SVT, ablation, devices, antiarrhythmic drugs, and high-impact trials. The Signal: physician-level analysis that identifies what matters in EP and translates evidence into clinical practice. EP Edge™: The Signal is the flagship monthly podcast from EP Edge, delivering structured, expert-level interpretation for electrophysiologists, cardiologists, fellows, and clinically engaged practitioners. Each episode goes beyond summaries to integrate evidence across trials, guidelines, mechanisms, and real-world practice. Episodes cover the full spectrum of electrophysiology, including atrial and ventricular arrhythmias, supraventricular tachycardias, antiarrhythmic pharmacology, pacing and defibrillator strategies, mapping and ablation technologies (including pulsed field ablation), and emerging data shaping clinical decision-making. This is not a news recap—it is a curated synthesis focused on what truly changes practice. Content combines mechanistic insight, cross-trial evidence review, critical appraisal of methodology and outcomes, and practical application in the EP lab and clinic. EP Edge™: The Signal complements the weekly EP Edge™: Journal Watch by providing deeper analysis and clinical synthesis. For patient-focused education, explore EP Edge™: Heart Talk. Available as both podcast and newsletter via EP Edge on LinkedIn and Substack: https://epedge.substack.com/

Language

🇺🇲

Publishing Since

10/27/2025

View on Apple Podcasts RSS Feed

2 verified contact emails on file for EP Edge™ The Signal

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

See contact details

Recent Episodes

February 25, 2026

EP Edge Newsletter Part III: Pulsed Field Ablation Complications — Hemolysis, Coronary Spasm, Silent Stroke, Phrenic Nerve Injury, and CIED Interaction

Pulsed field ablation (PFA) has rapidly transformed atrial fibrillation ablation, offering a non-thermal mechanism of myocardial injury through irreversible electroporation. While early clinical trials emphasized its favorable safety profile compared with radiofrequency and cryoablation, expanding real-world experience has revealed a distinct complication spectrum driven by high-voltage electric field interactions with myocardium, coronary arteries, blood, nerves, and cardiac implantable electronic devices. Unlike thermal injury, these complications are mediated by electrical, autonomic, and vascular effects, including delayed coronary vasospasm, malignant ventricular arrhythmias, and transient electrical instability. Understanding these mechanisms is critical as pulsed field ablation becomes more widely adopted in electrophysiology practice.This episode explores key complications including intravascular hemolysis and associated acute kidney injury, coronary artery spasm and ischemia, silent cerebral ischemic lesions, phrenic nerve injury, esophageal temperature elevation, and neuromuscular stimulation such as laryngospasm. These risks are strongly influenced by catheter design, lesion burden, waveform characteristics, and proximity to vulnerable structures. We also examine the interaction between pulsed field ablation and pacemakers and implantable cardioverter-defibrillators (ICDs), including transient pacing inhibition, electromagnetic interference, and rare cases of permanent device malfunction. As pulsed field ablation expands into more complex lesion sets and broader patient populations, recognizing these platform-specific risks is essential for procedural planning, patient selection, and post-procedural monitoring.Full references, detailed analysis, graphs, and visual summaries are available on the EP Edge Newsletter on LinkedIn, and the complete long-form article is also available on Substack at epedge.substack.com. If you have any questions, suggestions, or feedback, please contact epedgecast@gmail.com.

February 18, 2026

EP Edge Newsletter Part II: Pulsed Field Ablation Trials — ADVENT, PULSED AF, Sphere-9, VARIPULSE, VOLT, INSIGHT, and PULSAR

In this episode of the EP Edge Newsletter Podcast, we analyze the pivotal clinical trials that established pulsed field ablation (PFA) as a major technological advancement in atrial fibrillation ablation. We examine the foundational FDA-approval studies, including the PULSED AF trial evaluating the Medtronic PulseSelect system and the ADVENT randomized trial comparing FARAPULSE pulsed field ablation with conventional radiofrequency and cryoballoon ablation. These trials demonstrated that pulsed field ablation achieves high rates of acute pulmonary vein isolation with freedom from atrial arrhythmia recurrence comparable to thermal ablation, while maintaining a favorable safety profile and procedural efficiency. Importantly, these studies defined modern clinical endpoints for catheter ablation success, including composite measures incorporating arrhythmia recurrence, antiarrhythmic drug use, cardioversion, and repeat ablation. PFA Part IIWe also explore next-generation pulsed field ablation platforms, including the Sphere-9 lattice-tip catheter, VARIPULSE system, and VOLT balloon-in-basket catheter, each designed to improve lesion durability, catheter stability, and procedural reproducibility. These studies demonstrate consistently high rates of pulmonary vein isolation, favorable safety outcomes, and evolving workflow advantages, including reduced fluoroscopy use and efficient lesion delivery. We then examine the latest randomized and investigational trials, including INSIGHT, which compared nanosecond pulsed field ablation with optimized ablation-index guided radiofrequency ablation, and the PULSAR IDE trial evaluating spherical array catheter design for durable pulmonary vein isolation. These trials highlight a critical reality in atrial fibrillation ablation: long-term success is determined not only by energy source, but by catheter design, tissue contact, lesion geometry, and pulmonary vein isolation durability. PFA Part IIFull references, detailed discussion, figures, and graphical summaries are available on the EP Edge Newsletter on LinkedIn, as well as the complete long-form article on Substack at epedge.substack.com. If you have questions, suggestions, or feedback, please contact epedgecast@gmail.com.

February 11, 2026

EP Edge Newsletter Part I: Pulsed Field Ablation (PFA) — Electroporation, Biophysics, Engineering, Tissue Selectivity, and Lesion Formation

In this foundational episode of the EP Edge Newsletter Podcast, we examine the scientific and engineering principles underlying pulsed field ablation (PFA), a transformative advance in catheter ablation for atrial fibrillation. Unlike radiofrequency or cryoablation, which rely on thermal injury, pulsed field ablation produces myocardial lesions through irreversible electroporation, a non-thermal mechanism that disrupts the cell membrane by applying precisely controlled electric fields. This represents a fundamental shift in ablation biology, where lesion formation is governed not by heat, but by transmembrane voltage thresholds, membrane destabilization, and controlled cellular injury.This episode traces the history of electroporation, from its origins in physics and industrial biotechnology to its adoption in oncology as a non-thermal tumor ablation modality and eventual translation into cardiac electrophysiology. We then explore the Engineering Trinity of pulsed field ablation—the waveform, catheter, and pulse generator—and how these components interact to determine lesion size, safety profile, tissue selectivity, and procedural effectiveness. Understanding this integrated engineering system is essential to interpreting differences between pulsed field ablation platforms and explains why voltage alone does not define lesion durability or procedural success.We also examine the cellular and molecular mechanisms of PFA lesion formation, including nanopore creation within the lipid bilayer, calcium influx, ATP depletion, mitochondrial dysfunction, and regulated cell death pathways. These membrane-driven injury mechanisms produce lesions that differ fundamentally from thermal ablation, preserving extracellular architecture while eliminating cardiomyocytes. This unique biology underlies one of the most important advantages of pulsed field ablation—tissue selectivity, where myocardial cells demonstrate greater susceptibility to irreversible electroporation compared with surrounding structures such as the esophagus, nerves, and vasculature, enabling effective ablation with reduced collateral injury risk.Finally, we review the histopathology and structural evolution of pulsed field ablation lesions, including sharply demarcated injury zones, preserved tissue scaffolding, and progressive fibrocellular remodeling over time. These distinctive lesion characteristics explain both the safety profile and long-term behavior of pulsed field ablation and provide critical insight into how electrophysiologists should interpret acute procedural endpoints and long-term durability.Full references, detailed discussion, figures, and visual summaries are available on the EP Edge Newsletter on LinkedIn, as well as the full long-form edition on Substack at epedge.substack.com.If you have questions, suggestions, or feedback, please email epedgecast@gmail.com

11 total episodes available

Similar Podcasts

Discover related shows you might enjoy

The Lead Podcast presented by Heart Rhythm Society

This Week in Cardiology

Medscape

Up First

NPR

Deep-dive analytics for EP Edge™ The Signal

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is EP Edge™ The Signal?: Monthly clinical deep analysis in cardiac electrophysiology: AF, VT, SVT, ablation, devices, antiarrhythmic drugs, and high-impact trials. The Signal: physician-level analysis that identifies what matters in EP and translates evidence into clinical practice.

EP Edge™: The Signal is the flagship monthly podcast from EP Edge, delivering structured, expert-level interpretation for electrophysiologists, cardiologists, fellows, and clinically engaged practitioners. Each episode goes beyond summaries to integrate evidence across trials, guidelines, mechanisms, and real-world practice.

Episodes cover the full spectrum of electrophysiology, including atrial and ventricular arrhythmias, supraventricular tachycardias, antiarrhythmic pharmacology, pacing and defibrillator strategies, mapping and ablation technologies (including pulsed field ablation), and emerging data shaping clinical decision-making. This is not a news recap—it is a curated synthesis focused on what truly changes practice.

Content combines mechanistic insight, cross-trial evidence review, critical appraisal of methodology and outcomes, and practical application in the EP lab and clinic.

EP Edge™: The Signal complements the weekly EP Edge™: Journal Watch by providing deeper analysis and clinical synthesis. For patient-focused education, explore EP Edge™: Heart Talk. Available as both podcast and newsletter via EP Edge on LinkedIn and Substack: https://epedge.substack.com/
How often does this podcast release new episodes?: This podcast updates daily.
Where can I listen to this podcast?: This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Does this podcast accept guests?: No, this podcast does not typically feature guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.